Wealthcare Advisory Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Wealthcare Advisory Partners’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-125	Closed	-$2K	–	2032
2021 Q1	$2K	Buy	+125	New	+$2.16K	﹤0.01%	1936
2020 Q2	–	Sell	-125	Closed	-$2K	–	1469
2020 Q1	$2K	Hold	125	–	–	﹤0.01%	1340
2019 Q4	$3K	Buy	+125	New	+$2.59K	﹤0.01%	1228

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Wealthcare Advisory Partners's AERI Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Aerie Pharmaceuticals (AERI) in Q2 2021, closing a stake of 125 shares — an estimated $2K sold.

Wealthcare Advisory Partners first reported a position in AERI in Q4 2019 and held it in 3 quarters. The position peaked at $3K in Q4 2019. 142 funds tracked by Wall St. Rank hold AERI as of Q2 2021.

Wealthcare Advisory Partners reported no remaining Aerie Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 125 Aerie Pharmaceuticals shares in Q2 2021, an estimated $2K.
Wealthcare Advisory Partners first reported a position in Aerie Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Wealthcare Advisory Partners's Aerie Pharmaceuticals position peaked at $3K in Q4 2019.
142 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.